218 related articles for article (PubMed ID: 30551901)
1. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
2. Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.
Mook RA; Ren XR; Wang J; Piao H; Barak LS; Kim Lyerly H; Chen W
Bioorg Med Chem; 2017 Mar; 25(6):1804-1816. PubMed ID: 28233680
[TBL] [Abstract][Full Text] [Related]
3. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
[TBL] [Abstract][Full Text] [Related]
5. Small molecule modulators of Wnt/β-catenin signaling.
Mook RA; Chen M; Lu J; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2013 Apr; 23(7):2187-91. PubMed ID: 23453073
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
7. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
9. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
[TBL] [Abstract][Full Text] [Related]
10. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
12. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth.
Ono M; Yin P; Navarro A; Moravek MB; Coon V JS; Druschitz SA; Gottardi CJ; Bulun SE
Fertil Steril; 2014 May; 101(5):1441-9. PubMed ID: 24534281
[TBL] [Abstract][Full Text] [Related]
14. Niclosamide, a Drug with Many (Re)purposes.
Kadri H; Lambourne OA; Mehellou Y
ChemMedChem; 2018 Jun; 13(11):1088-1091. PubMed ID: 29603892
[TBL] [Abstract][Full Text] [Related]
15. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.
Osada T; Chen M; Yang XY; Spasojevic I; Vandeusen JB; Hsu D; Clary BM; Clay TM; Chen W; Morse MA; Lyerly HK
Cancer Res; 2011 Jun; 71(12):4172-82. PubMed ID: 21531761
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.
Li Z; Li Q; Wang G; Huang Y; Mao X; Zhang Y; Wang X
Am J Transl Res; 2017; 9(8):3776-3786. PubMed ID: 28861168
[TBL] [Abstract][Full Text] [Related]
17. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
18. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
Cell Death Dis; 2022 Feb; 13(2):112. PubMed ID: 35115509
[TBL] [Abstract][Full Text] [Related]
19. Effect of niclosamide on basal-like breast cancers.
Londoño-Joshi AI; Arend RC; Aristizabal L; Lu W; Samant RS; Metge BJ; Hidalgo B; Grizzle WE; Conner M; Forero-Torres A; Lobuglio AF; Li Y; Buchsbaum DJ
Mol Cancer Ther; 2014 Apr; 13(4):800-11. PubMed ID: 24552774
[TBL] [Abstract][Full Text] [Related]
20. Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improve Glucose and Lipid Metabolisms in Diet-Induced Obese Mice.
Obianom ON; Ai Y; Li Y; Yang W; Guo D; Yang H; Sakamuru S; Xia M; Xue F; Shu Y
J Med Chem; 2019 Jan; 62(2):727-741. PubMed ID: 30605343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
